Invizyne Technologies INC

eXoZymes Inc. has successfully closed a public offering of common stock and warrants, raising approximately $5.95 million in gross proceeds.

eXoZymes Inc. announced the pricing of its public offering of units, comprising common stock and warrants, expected to raise approximately $5.33 million.

eXoZymes Inc. has filed an 8-K detailing an investor presentation for a proposed public offering of securities.

eXoZymes Inc. has released an investor presentation on April 10, 2026, detailing information for potential underwriters and offering participants regarding a proposed securities offering.

EXOZYMES INC. filed an 8-K announcing an updated Investor Presentation related to its NCTx business as of March 30, 2026.

eXoZymes Inc. announced a successful 100-fold scale-up of N-trans-caffeoyltyramine (NCT) production with over 99% feedstock conversion using its proprietary exozyme platform.

eXoZymes Inc. reported a net loss of $2.37 million for Q1 2026, with a significant increase in R&D costs, while cash reserves decreased by over 50%.

eXoZymes Inc. reported a significant increase in net losses and cash burn for the nine months ended September 30, 2025, raising substantial doubt about its ability to continue as a going concern.

eXoZymes Inc. reported a significantly widened net loss and increased cash burn for Q2 2025, raising substantial doubt about its ability to continue as a going concern despite new grant awards.

eXoZymes Inc. reports a net loss of $1.86 million for Q1 2025, compared to a $1.01 million loss in Q1 2024, driven by increased operating costs.

Invizyne Technologies reported its Q3 2024 financial results, noting increased operating costs and a net loss, while also highlighting its recent IPO and future growth plans.

eXoZymes reported a wider 2025 net loss, sharply lower cash, and a going concern warning while advancing its NCT program and winning new grants.

eXoZymes Inc.'s 10-K filing provides a comprehensive overview of the company's capital stock, intellectual property, regulatory environment, and risk factors, highlighting its focus on biomanufacturing and its commercialization strategy.

ExoZymes Chief Scientific Officer, Tyler Korman, reports transactions involving the purchase of company common stock.

Damien Perriman, Chief Commercial Officer of ExoZymes Inc., was granted restricted stock and stock options on April 1, 2026, as detailed in a Form 4 filing.

Damien Alan Perriman, Chief Commercial Officer of ExoZymes Inc., acquired 8,887 shares of common stock on April 1, 2026.

ExoZymes Inc. Vice President Paul Opgenorth acquired 3,999 shares of common stock on April 1, 2026, increasing his beneficial ownership.

Fouad Nawaz, VP-Finance at ExoZymes Inc., reported a transaction involving the acquisition of 5,999 shares of common stock.

ExoZymes Chief Scientific Officer Tyler Korman acquired 5,332 shares of common stock on April 1, 2026.

ExoZymes Inc. filed an amendment to its proxy statement to correct an error on its proxy card, ensuring shareholders can properly vote for or withhold votes from director nominees.

eXoZymes Inc. has announced its 2025 Annual Meeting of Shareholders to be held virtually on July 25, 2025, seeking shareholder approval for director elections, executive compensation, a new performance equity plan, and auditor ratification.

Invizyne Technologies Inc. details the terms of a placement warrant agreement in its latest S-1/A filing, outlining conditions for purchasing common stock.

Invizyne Technologies Inc. files an amendment to its Form S-1 registration statement for its initial public offering, planning to list on the Nasdaq Capital Market under the symbol IZTC.

Invizyne Technologies Inc. is proceeding with its initial public offering, registering 3.75 million shares of common stock coupled with long-term investor rights, as detailed in Amendment No. 6 to its Form S-1 registration statement.

Invizyne Technologies Inc. files an amendment to its Form S-1 registration statement for a $15 million initial public offering, including a unique investor rights offering.

Invizyne Technologies Inc. has filed Amendment No. 4 to its Form S-1 registration statement, outlining details for its initial public offering and a secondary offering by a selling security holder.

Invizyne Technologies Inc. has filed an amendment to its Form S-1 registration statement for its initial public offering of 4,300,000 shares of common stock at $4.00 per share, while also registering shares for a selling security holder.